Biotech Values

[DewDiligence]

Perhaps he misspoke?

I wouldn’t call this an outright misstatement, but rather sloppy wording. I’m almost certain he meant that the two prodrugs resolve to the same monophosphate nucleotide. From that point forward, the monophosphate nuke gets converted to a triphosphate nuke in vivo, and hence the two prodrugs eventually produce the same triphosphate.

From a practical standpoint, it wouldn’t make much sense to have the prodrugs resolve to a triphosphate. This would weigh down the parent drugs with extra baggage and would gain little or nothing in terms of PK/PD.